SCHEMBL2192373

SCHEMBL2192373

O=C1CCCCCC1n1cnc2ccc(OCc3ccccc3)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 2/20 0.48
GRM5 P41594 1/20 0.41
PDE10A Q9Y233 1/20 0.38
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR1A P08908 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37
PKM P14618 1/20 0.36
SLC18A3 Q16572 1/20 0.36
SRC P12931 1/20 0.35
MT-CO2 P00403 2/20 0.35
ALOX5 P09917 2/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197007 0.99 HCAR1 (0.47) HCAR1GRM5PDE10AHTR3EHTR3B
SCHEMBL2195431 0.83 CDK1 (0.47) HCAR1GRM5PDE10AHTR3EHTR3B
SCHEMBL2194854 0.77 HCAR1 (0.48) HCAR1GRM5PDE10AHTR3EHTR3B
SCHEMBL2193329 0.76 HCAR1 (0.57) HCAR1SLC18A3SRC
SCHEMBL2192056 0.75 HCAR1 (0.56) HCAR1SLC18A3SRC
SCHEMBL31068655 0.69 PDE10A (0.48) GRM5PDE10AHTR3EHTR3BHTR1A
SCHEMBL2194786 0.68 PDE10A (0.70) HCAR1PDE10AHTR3EHTR3BHTR1A
SCHEMBL2194185 0.66 PDE10A (0.51) HCAR1PDE10AHTR3EHTR3BHTR1A
SCHEMBL16084159 0.65 HTR3E (0.42) HCAR1GRM5HTR3EHTR3BHTR1A
SCHEMBL17450227 0.64 CDK1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 HCAR1 28/4885GRM5 102/4885PDE10A 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.